Scarica l'app Stockscreener
42.59
4.25%
-1.89
Dopo l'orario di chiusura:
42.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on Ultragenyx with $95 target By Investing.com - Investing.com Australia
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Reports Strong Growth Amid Challenges - TipRanks
Ultragenyx Pharmaceutical Inc. SEC 10-K Report - TradingView
Inside Ultragenyx's Latest Executive Compensation Package: New Hires Receive Strategic RSU Grants - StockTitan
Canaccord Genuity Group Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $136.00 - MarketBeat
H.C. Wainwright maintains Buy on Ultragenyx with $95 target - Investing.com India
Peregrine Capital Management LLC Acquires 29,684 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Trend Tracker for (RARE) - Stock Traders Daily
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year By Investing.com - Investing.com South Africa
Canaccord raises Ultragenyx target to $136, keeps Buy rating By Investing.com - Investing.com Australia
Ultragenyx stock gains on FDA priority review (RARE:NASDAQ) - Seeking Alpha
Canaccord raises Ultragenyx target to $136, keeps Buy rating - Investing.com India
Ultragenyx Announces FDA Acceptance and Priority Review of - GlobeNewswire
Ultragenyx's Revolutionary Gene Therapy for Fatal Childhood Disease Advances: FDA Fast-Tracks Review - StockTitan
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from HC Wainwright - MarketBeat
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year - Investing.com India
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating - TipRanks
Ultragenyx stock holds Buy rating, $140 target from Truist - MSN
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Goldman Sachs maintains buy on Ultragenyx, target at $78 - MSN
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views - Benzinga
Cantor Fitzgerald maintains $118 target on Ultragenyx stock By Investing.com - Investing.com Nigeria
Goldman Sachs maintains buy on Ultragenyx, target at $78 By Investing.com - Investing.com South Africa
Ultragenyx stock holds Buy rating, $140 target from Truist By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highl - GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx: Q4 Earnings Snapshot - The Herald Review
Ultragenyx Pharmaceutical Reports Strong 2024 Growth - TipRanks
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
2 Anti-Kickback Developments Hold Lessons For Biopharma - Law360
ULTRAGENYX PHARMACEUTICAL Earnings Results: $RARE Reports Quarterly Earnings - Nasdaq
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Nasdaq
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):